Todd Aguilera
Radiation Oncology · San Diego, CANPI 1487934774
Payments from drug & device makers
What this record shows
This record is dominated by grants: $36,932 of the $45,420 with a category attached, or 81.3%. Genentech, Inc. accounts for 81.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $18,750 and has fallen 55.8% since, to $8,285 in 2025. Among radiation oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $1746.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$37K
- Novocure Inc.$8K
- Telix Pharmaceuticals$128
- Tempus AI, Inc$74
What the payments were for
- Speaking & faculty fees$6,30514%
- Grants$36,93281%
- Travel & lodging$9872%
- Food & beverage$1,1963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $36,932 |
| Novocure Inc. | 22 | $8,285 |
| Telix Pharmaceuticals | 1 | $128 |
| Tempus AI, Inc | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$257
How this compares
$45,420 in reported general payments places this provider in the 95th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 13 | $299 |
| Pantoprazole Sodium | 14 | $142 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in San Diego
- Jyoti MayadevSan Diego$170K
- Donald FullerSan Diego$34K
- Bradley PrestidgeSan Diego$22K
- Andrew SharabiSan Diego$21K
- Tyler SeibertSan Diego$21K
- Parag SanghviSan Diego$11K
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.